ReviewAntioxidants (Basel, Switzerland)2019
Anthocyanins and Their Metabolites as Therapeutic Agents for Neurodegenerative Disease.
Review in Antioxidants (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed, 2 syntheses or guidelines pooled it, 166 citations in OpenAlex.
- The effect of anthocyanins and anthocyanin-rich foods on cognitive function: a meta-analysis of randomized controlled trials.GeroScience · 2026Pooled it
- The Effects of Fruit-Derived Polyphenols on Cognition and Lung Function in Healthy Adults: A Systematic Review and Meta-Analysis.Nutrients · 2021Pooled it
- Assessing the Role of Dark Sweet Cherry (Nutrients · 2025Trial
- Short-term Aronia melanocarpa extract supplementation improves cognitive performance: a randomized, double-blind, placebo-controlled cross-over study in healthy young adults.European journal of nutrition · 2024Trial
- Feasibility and Preliminary Efficacy of American Elderberry Juice for Improving Cognition and Inflammation in Patients with Mild Cognitive Impairment.International journal of molecular sciences · 2024Trial
- The Effect of Long-TermNutrients · 2020Trial
- Prostaglandins: Key players in immunomodulation of the nervous system.Neural regeneration research · 2026Article
- Effects of dietary mulberry anthocyanins on meat quality, antioxidant capacity, gut microbiota, and plasma anthocyanin exposure in North China Chai chickens.Poultry science · 2026Article
- Article
- Neuroprotective role of cyanidin in Alzheimer's and Parkinson's disease: current insights and the road ahead.Inflammopharmacology · 2026Review
- Impact of Oxidative Stress-Driven Ferroptosis in Neurodegeneration.International journal of molecular sciences · 2026Review
- Activation of the NR3C1-STAT3-SLC6A2 signaling axis by a cyanidin-3-O-glucoside-enriched anthocyanin preparation attenuates neuroinflammation and pain hypersensitivity in intervertebral disc degeneration.Journal of neuroinflammation · 2026Article
- Review
- Polyphenol metabolites in fermented foods: biotransformation, bioavailability, and functional roles.Frontiers in nutrition · 2026Review
- The role of flower consumption in Howler Monkey Females' diet: adjustment across reproductive states.PeerJ · 2026Article
- Causal Effects Between Neurodegenerative Diseases, Metabolites, and Brain Volume.Current Alzheimer research · 2026Article
- A Randomized Controlled Trial on the Safety and Cognitive Benefits of a Novel Functional Drink from a Purple Waxy Corn Byproduct in Peri- and Postmenopausal Women.Antioxidants (Basel, Switzerland) · 2025Article
- Emerging anti-inflammatory nanosystems targeted to the brain.Nanomedicine (London, England) · 2025Review
- Review: Enhancing the Bioavailability and Stability of Anthocyanins for the Prevention and Treatment of Central Nervous System-Related Diseases.Foods (Basel, Switzerland) · 2025Review
- Toxicological screening of jambolan hydroalcoholic extract (Toxicology reports · 2025Article
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS), are characterized by the death of neurons within specific regions of the brain or spinal cord. While the etiology of many neurodegenerative diseases remains elusive, several factors are thought to contribute to the neurodegenerative process, such as oxidative and nitrosative stress, excitotoxicity, endoplasmic reticulum stress, protein aggregation, and neuroinflammation. These processes culminate in the death of vulnerable neuronal populations, which manifests symptomatically as cognitive and/or motor impairments. Until recently, most treatments for these disorders have targeted single aspects of disease pathology; however, this strategy has proved largely ineffective, and focus has now turned towards therapeutics which target multiple aspects underlying neurodegeneration. Anthocyanins are unique flavonoid compounds that have been shown to modulate several of the factors contributing to neuronal death, and interest in their use as therapeutics for neurodegeneration has grown in recent years. Additionally, due to observations that the bioavailability of anthocyanins is low relative to that of their metabolites, it has been proposed that anthocyanin metabolites may play a significant part in mediating the beneficial effects of an anthocyanin-rich diet. Thus, in this review, we will explore the evidence evaluating the neuroprotective and therapeutic potential of anthocyanins and their common metabolites for treating neurodegenerative diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.